Registry for esophageal and gastric cancer data collection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive database for esophageal and gastric cancer patients, facilitating epidemiological and clinical research. Data will be collected retrospectively from medical records of adult patients diagnosed with these cancers, ensuring rigorous data management and analysis. The initiative is designed to enhance understanding of these cancers, optimize patient management, and improve the quality of scientific publications in the field.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown).
* Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause.

Exclusion Criteria:

* A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.

Where it's running

• Hospital General Universitario de Alicante
  Alicante, Alicante, Spain Recruiting
• Hospital General Universitario de Elche
  Elche, Alicante, Spain Recruiting
• Hospital General Universitario de Elda
  Elda, Alicante, Spain Recruiting
• Hospital Universitario Reina Sofia
  Córdoba, Andalusia, Spain Recruiting
• Hospital Regional Universitario de Málaga
  Málaga, Andalusia, Spain Recruiting
• Hospital Universitario Virgen Macarena
  Seville, Andalusia, Spain Recruiting

Study contacts

• Principal investigator: Paula Dr Jiménez Fonseca, MD-PhD — Sociedad Española de Oncología Medica (SEOM)
• Study coordinator: Paula Dr Jiménez Fonseca, MD-PhD
• Email: palucaji@hotmail.com
• Phone: 985106121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Molecular comparison of primary gastroesophageal cancers and their brain metastases

  This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07464470

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

• PET imaging that targets CLDN18.2 to find stomach, pancreatic, bile-duct, and esophageal cancers

  This project will try a CLDN18.2-targeted PET scan in adults with suspected or confirmed gastric, pancreatic, bile-duct, or esophageal cancer (and some healthy volunteers) to see if it can show CLDN18.2-positive tumors.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301814

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.